572 related articles for article (PubMed ID: 20825620)
21. Inconsistencies in TTO and VAS values for EQ-5D health states.
Lamers LM; Stalmeier PF; Krabbe PF; Busschbach JJ
Med Decis Making; 2006; 26(2):173-81. PubMed ID: 16525171
[TBL] [Abstract][Full Text] [Related]
22. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
Fautrel B; Clarke AE; Guillemin F; Adam V; St-Pierre Y; Panaritis T; Fortin PR; Menard HA; Donaldson C; Penrod JR
J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
[TBL] [Abstract][Full Text] [Related]
23. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
Olofsson S; Norrlid H; Persson U
J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
[TBL] [Abstract][Full Text] [Related]
24. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
[TBL] [Abstract][Full Text] [Related]
25. Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.
Lankarani KB; Ghahramani S; Moradi N; Shahraki HR; Lotfi F; Honarvar B
Appl Health Econ Health Policy; 2018 Dec; 16(6):837-846. PubMed ID: 30123949
[TBL] [Abstract][Full Text] [Related]
26. Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.
Reckers-Droog V; van Exel J; Brouwer W
Value Health; 2021 Aug; 24(8):1182-1192. PubMed ID: 34372984
[TBL] [Abstract][Full Text] [Related]
27. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences.
Martín-Fernández J; Polentinos-Castro E; del Cura-González MI; Ariza-Cardiel G; Abraira V; Gil-LaCruz AI; García-Pérez S
BMC Health Serv Res; 2014 Jul; 14():287. PubMed ID: 24989615
[TBL] [Abstract][Full Text] [Related]
28. Estimating a constant WTP for a QALY-a mission impossible?
Sund B; Svensson M
Eur J Health Econ; 2018 Jul; 19(6):871-880. PubMed ID: 28932914
[TBL] [Abstract][Full Text] [Related]
29. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
Huang L; Peng X; Sun L; Zhang D
Cost Eff Resour Alloc; 2023 Jun; 21(1):37. PubMed ID: 37277820
[TBL] [Abstract][Full Text] [Related]
30. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
Ye Z; Abduhilil R; Huang J; Sun L
Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
[TBL] [Abstract][Full Text] [Related]
31. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
Shiroiwa T; Sung YK; Fukuda T; Lang HC; Bae SC; Tsutani K
Health Econ; 2010 Apr; 19(4):422-37. PubMed ID: 19382128
[TBL] [Abstract][Full Text] [Related]
32. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
Nielsen JS; Gyrd-Hansen D; Kjaer T
Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
[TBL] [Abstract][Full Text] [Related]
33. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Thavorncharoensap M; Teerawattananon Y; Natanant S; Kulpeng W; Yothasamut J; Werayingyong P
Clinicoecon Outcomes Res; 2013; 5():29-36. PubMed ID: 23345984
[TBL] [Abstract][Full Text] [Related]
34. Investigating the social value of health changes.
Gyrd-Hansen D
J Health Econ; 2004 Nov; 23(6):1101-16. PubMed ID: 15556238
[TBL] [Abstract][Full Text] [Related]
35. WTP for a QALY and health states: More money for severer health states?
Shiroiwa T; Igarashi A; Fukuda T; Ikeda S
Cost Eff Resour Alloc; 2013; 11():22. PubMed ID: 24128004
[TBL] [Abstract][Full Text] [Related]
36. Willingness to pay for a hearing aid: comparing the payment scale and open-ended question.
Grutters JP; Anteunis LJ; Chenault MN; Joore MA
J Eval Clin Pract; 2009 Feb; 15(1):91-6. PubMed ID: 19239587
[TBL] [Abstract][Full Text] [Related]
37. Valuing QALY gains by applying a societal perspective.
Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
Health Econ; 2013 Oct; 22(10):1272-81. PubMed ID: 23080321
[TBL] [Abstract][Full Text] [Related]
38. The value of dementia care towards the end of life-A contingent valuation study.
Bhattarai N; Mason H; Kernohan A; Poole M; Bamford C; Robinson L; Vale L
Int J Geriatr Psychiatry; 2020 May; 35(5):489-497. PubMed ID: 31912572
[TBL] [Abstract][Full Text] [Related]
39. Willingness to pay for health care services in common cold, retinal detachment, and myocardiac infarction: an internet survey in Japan.
Yasunaga H; Ide H; Imamura T; Ohe K
BMC Health Serv Res; 2006 Feb; 6():12. PubMed ID: 16504017
[TBL] [Abstract][Full Text] [Related]
40. Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone.
Pinto-Prades JL; Farreras V; de Bobadilla JF
Eur J Health Econ; 2008 Feb; 9(1):69-78. PubMed ID: 17447095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
